EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Severity and Cost of Respiratory Syncytial Virus Versus Influenza in Hospitalized Adults in Spain

Elisa Correcher-Martínez, Cintia Muñoz-Quiles iD, Mónica López-Lacort, Ainara Mira-Iglesias iD, María Díaz-López, Beatriz Mengual-Chuliá iD, F Xavier López-Labrador iD, Javier Díez-Domingo, Alejandro Orrico-Sánchez

Influenza and Other Respiratory Viruses · 2026-04 · 20 (4)

DOI: 10.1111/irv.70254 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, online erschienen am 22.04.2026. Verfasst von Elisa Correcher-Martínez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vaccines Research Unit. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valenc…. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, Hospitalization, Influenza, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Respiratory syncytial virus (RSV) can lead to severe outcomes, particularly in older and vulnerable adults, yet it remains underdiagnosed due to limited testing. This study compared the severity and costs of laboratory‐confirmed RSV versus influenza hospitalizations.

Methods

We performed a retrospective analysis using data from the Valencia Hospital Network for the Study of Infectious Diseases (VAHNSI), covering up to 46% of the Valencia Region's population. Hospitalized influenza‐like illness (ILI) cases in individuals aged ≥ 65 years across six seasons (2014/15–2019/20) were included. RSV and influenza were identified by multiplex RT‐PCR. Outcomes assessed included mechanical ventilation (MV), hospital length of stay (LOS), in‐hospital death, 30‐day post‐discharge death, and hospitalization costs. Logistic and log‐normal regression models were used to compare severity and cost outcomes between RSV and influenza, adjusting for age, sex, comorbidities, and influenza vaccination status. Odds ratios (ORs) and mean ratios (MRs) with 95% confidence intervals (CIs) were calculated.

Results

Of 1954 hospitalizations, 429 (22%) were due to RSV and 1525 (78%) to influenza. RSV cases showed higher MV use (9.26% vs. 4.15%; adjusted OR 2.43 [95% CI: 1.61–3.67]) and longer LOS (7.7 vs. 6.8 days; adjusted MR 1.10 [95% CI: 1.02–1.19]). Mortality outcomes were similar. RSV hospitalizations incurred 6% higher mean costs (€3907 vs. €3806).

Conclusions

RSV hospitalizations in older adults were less frequent but more severe and costly than influenza, with comparable mortality. These findings highlight the importance of RSV prevention and support the development of targeted vaccination programs for the elderly.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Syncytial Virus InfectionsHospitalizationInfluenza, HumanHumansSpainFemaleRetrospective StudiesAgedMaleAged, 80 and overSeverity of Illness IndexLength of StayRespiratory Syncytial Virus, Human

Stichwörter der Autor:innen

adultshospital mortalityhospitalizationinfluenzalength of staymonitoringprospectiverespiratory syncytial virusretrospectivereverse transcriptase polymerase chain reaction

Autor:innen und Institutionen

  • Vaccines Research Unit. Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain.
  • CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain.
  • Virology Laboratory, Genomics and Health Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO-Public Health, Valencia, Spain.
  • Universidad Católica de Valencia San Vicente Mártir, Valencia, Spain.

ORCID-Profile: Cintia Muñoz-Quiles, Ainara Mira-Iglesias, Beatriz Mengual-Chuliá, F Xavier López-Labrador

Förderung

  • Merck Sharp & Dohme LLC
  • Instituto de Salud Carlos III

Zitieren

APA

Correcher-Martínez, E., Muñoz-Quiles, C., López-Lacort, M., Mira-Iglesias, A., Díaz-López, M., Mengual-Chuliá, B., López-Labrador, F. X., Díez-Domingo, J., & Orrico-Sánchez, A. (2026). Severity and Cost of Respiratory Syncytial Virus Versus Influenza in Hospitalized Adults in Spain. Influenza and Other Respiratory Viruses, 20(4). https://doi.org/10.1111/irv.70254

Vancouver

Correcher-Martínez E, Muñoz-Quiles C, López-Lacort M, Mira-Iglesias A, Díaz-López M, Mengual-Chuliá B, et al. Severity and Cost of Respiratory Syncytial Virus Versus Influenza in Hospitalized Adults in Spain. Influenza and Other Respiratory Viruses. 2026;20(4). doi:10.1111/irv.70254

BibTeX
@article{CorrecherMartnez2026,
  author = {Correcher-Martínez, Elisa and Muñoz-Quiles, Cintia and López-Lacort, Mónica and Mira-Iglesias, Ainara and Díaz-López, María and Mengual-Chuliá, Beatriz and López-Labrador, F Xavier and Díez-Domingo, Javier and Orrico-Sánchez, Alejandro},
  title = {Severity and Cost of Respiratory Syncytial Virus Versus Influenza in Hospitalized Adults in Spain},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2026},
  volume = {20},
  number = {4},
  doi = {10.1111/irv.70254}
}
Kostenlos starten →